CA
NZ
UK
AU
IND
US
…
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases. Its pipeline includes NPM-139 for chronic weight management in patients who are obese or overweight; NPM-133 a semaglutide implant for the treatment of patients with type 2 diabetes; NPM-115, an exenatide implant candidate for chronic weight management in patients who are obese or overweight; and OKV-119, an exenatide implant for the treatment of obesity and diabetes in companion animals, including cats and dogs. The company is headquartered in Alameda, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Public information on Vivani Medical Inc. (NASDAQ: VANI) is limited; the company describes itself as a medical technology firm developing clinical solutions for wound care and related diagnostics. Long-term growth may depend on clinical validation, successful commercialization, reimbursement adoption and scaling of its technology, and investors may find exposure to data-driven clinical tools addressing chronic care needs attractive if those milestones are achieved.
Material risks include limited disclosure and operating history, development-stage status requiring additional financing, regulatory and clinical hurdles, and significant execution and market-competition risk.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -26.61M | -23.49M | -25.65M | -13.89M | -12.77M |
| Net income | -26.61M | -23.49M | -25.65M | -6.54M | -12.13M |
| Selling general administrative | 9.43M | 8.93M | 10.00M | 7.07M | 2.32M |
| Selling and marketing expenses | - | - | 0.36M | - | - |
| Gross profit | -0.42M | -0.40M | -0.36M | - | 0.00M |
| Reconciled depreciation | 0.42M | 0.40M | 0.37M | 0.38M | 0.34M |
| Ebit | -26.61M | -23.49M | -25.65M | -21.24M | -13.32M |
| Ebitda | -26.18M | -23.09M | -25.30M | -27.74M | -13.62M |
| Depreciation and amortization | 0.42M | 0.40M | 0.36M | -6.50M | -0.30M |
| Operating income | -27.56M | -24.68M | -26.96M | -21.24M | -13.32M |
| Other operating expenses | 27.56M | 24.68M | 26.96M | 21.24M | 13.32M |
| Interest expense | - | - | - | -7.35M | 0.55M |
| Income tax expense | - | -23.49M | - | -7.35M | -0.64M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 27.13M | 24.68M | 26.61M | 21.24M | 13.32M |
| Cost of revenue | 0.42M | 0.40M | 0.36M | - | 0.00M |
| Total other income expense net | 0.95M | 1.19M | 1.31M | 7.35M | 0.55M |
| Net income from continuing ops | -26.61M | -23.49M | -26.91M | -13.89M | -12.77M |
| Net income applicable to common shares | - | - | - | - | -8.92M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 39.39M | 41.56M | 45.80M | 51.13M | 5.45M |
| Other current assets | 1.01M | 1.84M | 2.41M | 2.45M | 0.29M |
| Total liab | 23.66M | 23.95M | 25.04M | 6.82M | 2.99M |
| Total stockholder equity | 15.73M | 17.61M | 20.76M | 44.31M | 2.46M |
| Other current liab | 3.78M | 3.82M | 3.46M | 4.69M | 0.90M |
| Common stock | 0.01M | 0.01M | 0.01M | 109.05M | 54.65M |
| Capital stock | 0.01M | 0.01M | 0.01M | 109.05M | 54.65M |
| Retained earnings | -148.53M | -121.92M | -98.44M | -72.79M | -58.90M |
| Other assets | - | - | 0.00M | - | 0.03M |
| Cash | 16.23M | 18.35M | 20.65M | 45.08M | 2.18M |
| Total current liabilities | 6.60M | 5.99M | 5.72M | 6.82M | 2.09M |
| Current deferred revenue | - | - | 0.34M | - | - |
| Net debt | 2.62M | 0.96M | 0.04M | -44.12M | -0.37M |
| Short term debt | 1.79M | 1.35M | 1.38M | 0.95M | 0.91M |
| Short long term debt total | 18.86M | 19.31M | 20.70M | 0.95M | 1.81M |
| Other stockholder equity | 164.22M | 139.48M | 119.05M | 8.01M | 6.71M |
| Property plant equipment | - | - | - | - | 0.34M |
| Total current assets | 17.90M | 20.44M | 23.06M | 47.53M | 2.47M |
| Net tangible assets | - | - | - | - | 68.36M |
| Net receivables | 0.65M | 0.25M | - | - | - |
| Accounts payable | 1.03M | 0.82M | 0.54M | 1.18M | 0.28M |
| Accumulated other comprehensive income | 0.03M | 0.05M | 0.14M | 0.04M | -0.38M |
| Non currrent assets other | 0.05M | 0.13M | 0.05M | 1.64M | 0.20M |
| Non current assets total | 21.50M | 21.12M | 22.73M | 3.60M | 2.98M |
| Capital lease obligations | 18.86M | 19.31M | 20.70M | 0.95M | 1.81M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -0.56M | -0.18M | -0.34M | -0.57M |
| Change to liabilities | - | - | - | - | 0.06M |
| Total cashflows from investing activities | -1.17M | -0.56M | -0.89M | - | -0.01M |
| Net borrowings | 0.01M | 0.43M | 0.00M | - | -2.20M |
| Total cash from financing activities | 23.27M | 19.05M | 0.13M | 63.39M | 11.62M |
| Change to operating activities | - | - | - | - | -0.48M |
| Net income | -26.61M | -23.49M | -25.65M | -13.89M | -12.77M |
| Change in cash | -2.12M | -2.30M | -24.45M | 44.26M | 0.10M |
| Begin period cash flow | 19.69M | 21.99M | 46.44M | 2.18M | 2.08M |
| End period cash flow | 17.57M | 19.69M | 21.99M | 46.44M | 2.18M |
| Total cash from operating activities | -24.32M | -20.79M | -23.70M | -18.79M | -10.95M |
| Issuance of capital stock | 23.29M | 18.82M | 0.13M | 0.02M | 11.62M |
| Depreciation | 0.42M | 0.40M | 0.36M | 0.38M | 0.34M |
| Other cashflows from investing activities | - | -13.69M | - | - | - |
| Change to account receivables | -0.40M | - | - | - | - |
| Sale purchase of stock | -0.03M | - | - | - | - |
| Other cashflows from financing activities | - | -18.82M | 0.13M | 63.37M | -0.57M |
| Change to netincome | - | - | - | - | 0.08M |
| Capital expenditures | 1.17M | 0.56M | 0.89M | 0.34M | 0.57M |
| Change in working capital | 0.23M | 0.35M | -1.29M | 0.34M | 0.45M |
| Stock based compensation | 1.48M | 1.61M | 1.86M | 1.30M | 1.67M |
| Other non cash items | 0.15M | 0.34M | 1.02M | -6.91M | -0.64M |
| Free cash flow | -25.49M | -21.34M | -24.59M | -19.12M | -11.52M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| VANI Vivani Medical Inc. |
-0.03 2.75% |
1.06 | - | - | - | 5.99 | -3.93 |
| NVO Novo Nordisk A/S |
-0.24 0.61% |
40.20 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-21.28 3.85% |
531.87 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
12.10 1.26% |
973.36 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases. Its pipeline includes NPM-139 for chronic weight management in patients who are obese or overweight; NPM-133 a semaglutide implant for the treatment of patients with type 2 diabetes; NPM-115, an exenatide implant candidate for chronic weight management in patients who are obese or overweight; and OKV-119, an exenatide implant for the treatment of obesity and diabetes in companion animals, including cats and dogs. The company is headquartered in Alameda, California.
| Name | Title | Year Born |
|---|---|---|
| Mr. Adam Mendelsohn Ph.D. | Co-Founder, Chairman & CEO | NA |
| Mr. Truc Le M.B.A. | Chief Operations Officer | 1953 |
| Dr. Lisa E. Porter M.D. | Chief Medical Officer | 1964 |
| Mr. Donald Dwyer M.B.A. | Chief Bus. Officer | NA |
| Dr. Kayte Fischer Ph.D. | Co-Founder | NA |
| Ms. Brigid Ann Makes | Chief Financial Officer | 1956 |
| Mr. Adam Mendelsohn Ph.D. | Co-Founder, CEO & Director | 1982 |
| Mr. Donald Dwyer M.B.A. | Chief Business Officer | NA |
| Dr. Adam Mendelsohn Ph.D. | Co-Founder, CEO & Director | 1982 |
| Mr. Anthony Edward Baldor M.B.A. | Chief Financial Officer | 1982 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.39%
Communication Services
+0.40%
Consumer Cyclical
-0.20%
Consumer Defensive
-0.56%
Energy
-0.45%
Financial Services
-0.09%
Financials
+0.11%
Healthcare
+0.40%
Industrials
+0.34%
Real Estate
-0.14%
Technology
+0.88%
Utilities
+0.11%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...